1. 93O First results of phase I/II studies evaluating viral vector-based heterologous prime/boost immunotherapy against predicted HLA class I neoantigens demonstrate CD8 T cell responses in patients with advanced cancers. (15th December 2019) Authors: Johnson, M L; Spira, A; Carbone, D P; Drake, C; Henick, B; Ingham, M; Caldwell, K; Chan, S; Hart, M; Malloy, A; Maloney, E; Palmer, C; Yang, A; Zhong, M; Basciano, P; Bournazou, E; Ferguson, A R; Catenacci, D Journal: Annals of oncology Issue: Volume 30(2019)Supplement 11 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗